Minocycline 100mg: Capsules Minocycline 100mg po per day and placebo 100mg po per day for 12 months
Minocycline 200mg: Capsules Minocycline 100mg po twice a day for 12 months
Placebo: Capsules placebo 100mg po twice a day for 12 months
Study summary
This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety(100mg/d, 200mg/d) for Retinitis pigmentosa and to find the optimal treatment dose.
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* Age should be between 18 and 60 years old.
* Clinically diagnosed with retinitis pigmentosa, characterized by reduced electroretinogram (ERG) responses and constricted visual fields.
* In at least one eye, the amplitude of the 30Hz flicker ERG under photopic conditions should not be lower than 0 microvolts.
* The best-corrected visual acuity (BCVA, ETDRS) in both eyes should not be lower than 0.
Exclusion Criteria:
* Allergic to tetracycline antibiotics.
* Pregnant or breastfeeding.
* Syndromic retinitis pigmentosa.
* Currently taking tetracycline antibiotics or any medications that may have adverse interactions with minocycline.
* Currently participating in or having participated in another investigational study within the past 6 months.
* Presence of other ocular diseases, including glaucoma, uveitis, age-related macular degeneration, diabetic retinopathy, etc.
* History of ocular surgical intervention.
* History of uncontrolled severe comorbid conditions, such as renal disease, liver disease, autoimmune disease, thyroid dysfunction, psychiatric disorders, or idiopathic intracranial hypertension.
* Inability of the participant to comply with the study-required procedures, such as epilepsy, inability to fixate, or allergy to fluorescein. Inability to understand the content of the study, sign the informed consent form, or comply with the study procedures or follow-up visits.
* Inability to swallow capsules.
Primary outcome measure(s)
The change of ERG — 12 months The proportion of patients in the group who showed an increase in the amplitude of the light-adapted 30Hz flicker ERG response at 12 months post-treatment compared to baseline.
Trial sites (1)
Facility
City
Region
Status
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou
Guangdong
More Zhongshan Ophthalmic Center, Sun Yat-sen University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.